AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24048627
Drug: Sunitinib 25
RxNorm normalized name: sunitinib 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 25 mg daily
Trial: 24048627
Drug: Sunitinib 37.5
RxNorm normalized name: sunitinib 37.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 37.5 mg daily
Trial: 24048627
Drug: Intensity modulated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensity modulated radiation therapy (50.4 Gy in 28 fractions)
Trial: 24048673
Drug: GLP-1 co-infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 co-infusion during hyperglycaemic clamps
Trial: 24048673
Drug: GIP co-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIP co-infusion during hyperglycaemic clamps
Trial: 24048673
Drug: Saline co-infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline co-infusion during hyperglycaemic clamps
Trial: 24050953
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily orally until unacceptable toxicity or disease progression
Trial: 24050955
Drug: Post-diagnostic β-blocker
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-diagnostic β-blocker use
Trial: 24050955
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no β-blocker use)
Trial: 24052462
Drug: Once-monthly continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-monthly continuous erythropoietin receptor activator (CERA)
Trial: 24053191
Drug: Lanreotide Autogel,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide Autogel, 120 mg every 28 days over ≤92 weeks
Trial: 24055176
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with various treatments for T2DM
Trial: 24056477
Drug: Universal MRSA
RxNorm normalized name: STATLOCK UNIVERSAL PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal MRSA screening with contact precautions and decolonisation (intranasal mupirocin and chlorhexidine bathing)
Trial: 24056477
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of enhanced hand hygiene and MRSA screening with contact precautions and decolonisation
Trial: 24058078
Drug: Paclitaxel-iopromide-coated balloon
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²)
Trial: 24058078
Drug: Paclitaxel-iopromide-coated balloon
RxNorm normalized name: Iopromide
DrugBank: Iopromide (DB09156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paclitaxel-iopromide-coated balloon catheter (3 µg/mm²) + Bare metal stent (BMS)
Trial: 24059479
Drug: Balanced solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balanced solution (BS) group
Trial: 24059479
Drug: Unbalanced solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unbalanced solution (UBS) group
Trial: 24062399
Drug: First-line chemotherapy
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line chemotherapy for cancer
Trial: 24062399
Drug: Low Instrumental
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Instrumental Activities of Daily Living (IADL) scores
Trial: 24062895
Drug: NT-proBNP levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP levels below median (5000 pg/ml)
Trial: 24063698
Drug: Olaparib 200
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 200 mg bid continuously plus weekly paclitaxel 90 mg/m2 for three weeks per four-week cycle
Trial: 24064228
Drug: Cooling initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling initiated with surface cooling pads, followed by 1000-2000 mL of cold saline at hospital arrival and endovascular cooling in the catheterisation laboratory.
Trial: 24064318
Drug: Partial breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT) to a prescribed dose of 38.5 Gy in 10 fractions.
Trial: 24064318
Drug: Partial breast
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial breast irradiation (PBI) using external beam 3-dimensional conformal radiation therapy (RT).
Trial: 24065152
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (weight gain >4%)
Trial: 24065152
Drug: Insulin therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin therapy (weight gain no or little)
Trial: 24068762
Drug: Pharmacist prescribing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist prescribing intervention (10 units of insulin glargine at bedtime, adjusted by increments of 1 unit daily)
Trial: 24070065
Drug: aPC infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aPC infusion (24 mcg/kg/h for 96 hours)
Trial: 24073008
Drug: Ayurvedic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayurvedic treatment
Trial: 24075534
Drug: Bortezomib 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.2 mg/m(2) and idarubicin 8 mg/m(2)
Trial: 24075534
Drug: Bortezomib 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 0.8 mg/m(2) and idarubicin 10 mg/m(2)
Trial: 24075534
Drug: Bortezomib 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bortezomib 1.0 mg/m(2) and idarubicin 10 mg/m(2)
Trial: 24075534
Drug: Bortezomib and
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib and idarubicin combination
Trial: 24075891
Drug: Capsule endoscopy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule endoscopy (CE)
Trial: 24076532
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial volume index (LAVi) ≥32 ml/m²
Trial: 24076532
Drug: LAVi ≥32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAVi ≥32 ml/m²
Trial: 24076532
Drug: LAVi <32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAVi <32 ml/m²
Trial: 24076699
Drug: Nonanimal stabilized
RxNorm normalized name: nonanal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonanimal stabilized hyaluronic acid gel (mean of 163 ml per buttock)
Trial: 24076699
Drug: Nonanimal stabilized
RxNorm normalized name: nonanal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonanimal stabilized hyaluronic acid gel
Trial: 24077846
Drug: Imatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib plus sequential chemotherapy followed by autologous stem cell transplantation
Trial: 24077916
Drug: Neratinib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (200 mg/day) with trastuzumab (4 mg/kg IV loading dose, then 2 mg/kg IV weekly) and paclitaxel (80 mg/m2 IV days 1, 8, and 15 of a 28-day cycle)
Trial: 24077916
Drug: Neratinib (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neratinib (120 up to 240 mg/day) with trastuzumab and paclitaxel
Trial: 24079262
Drug: Physical examination
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical examination to guide fluid therapy
Trial: 24079716
Drug: Rotarix (RIX4414)
DrugBank: Rotavirus vaccine (DB10276)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotarix (RIX4414) - two doses (0, 2-month schedule)
Trial: 24079992
Drug: PRIME intervention
RxNorm normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PRIME intervention (Health Centre Management, Fever Case Management, Patient-Centered Services, support for supplies of malaria diagnostics and antimalarial drugs)
Trial: 24081577
Drug: Clofarabine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofarabine (20 mg/m² × 5 days) plus low-dose cytarabine (20 mg/m² × 14 days)
Trial: 24089587
Drug: Infliximab (IFX)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab (IFX) 5 mg/kg every 6 weeks for 56 weeks, then reduced to 3 mg/kg every 8 weeks during the second year, with concomitant MTX at median dose 7.5 mg/week.
Trial: 24090033
Drug: Home administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home administration of pemetrexed maintenance therapy (500 mg/m² every 3 weeks until progressive disease or unacceptable toxicity)
Trial: 24090077
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg oral dose of DMAA
Trial: 24092933
Drug: Azacitidine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine (75 mg/m² for 7 days) and Gemtuzumab ozogamicin (3 mg/m² on day 8)
Trial: 24093426
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg CHP-NY-ESO-1 vaccine
Trial: 24093426
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg CHP-NY-ESO-1 vaccine
Trial: 24095247
Drug: Setipiprant capsule
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant capsule (2 250-mg capsules)
Trial: 24095247
Drug: Setipiprant tablet
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant tablet (500-mg tablet)
Trial: 24097022
Drug: Step 1
RxNorm normalized name: Nicotine Patch Step 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 1 analgesic (mainly paracetamol)
Trial: 24097022
Drug: Step 2
RxNorm normalized name: STEP 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 2 analgesic (23% dextropropoxyphene and 40.3% tramadol/paracetamol combination)
Trial: 24097022
Drug: Step 3
RxNorm normalized name: Nicotine Patch Step 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Step 3 analgesics
Trial: 24097022
Drug: No analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No analgesic medication
Trial: 24098507
Drug: Netazepide (YF476)
RxNorm normalized name: Netazepide
DrugBank: Netazepide (DB12355)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Netazepide (YF476) administered orally for 12 weeks
Trial: 24099345
Drug: Thrice-weekly rifampicin-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly rifampicin-based therapy
Trial: 24099518
Drug: T4 immunotherapy
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 immunotherapy (T4(+) T-cells) administered intratumorally at doses starting from 10^7 cells to 10^9 cells.
Trial: 24099518
Drug: T4 immunotherapy
RxNorm normalized name: T4
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: T4 immunotherapy (T4(+) T-cells) administered intratumorally with low- or high-dose cyclophosphamide before 10^9 T4(+) T-cells.
Trial: 24099585
Drug: Cabazitaxel (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (12 mg/m²)
Trial: 24099585
Drug: Cabazitaxel (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (10 mg/m²)
Trial: 24099585
Drug: Cabazitaxel (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (weekly administration)
Trial: 24099585
Drug: Cabazitaxel (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabazitaxel (6-12 mg/m² doses)
Trial: 24099865
Drug: Oxaliplatin 120
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 120 mg/m² and pemetrexed 500 mg/m² intravenously every 21 days
Trial: 24100924
Drug: Erlotinib (dose-intense)
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib (dose-intense)
Trial: 24101373
Drug: Tafamidis 20
RxNorm normalized name: TAFAMIDIS 20MG TAB UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tafamidis 20 mg QD for 12 months
Trial: 24102029
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy (treated with statins)
Trial: 24105751
Drug: Acetyl-L-carnitine (ALC)
RxNorm normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl-L-carnitine (ALC) 1,000 mg every 3 days
Trial: 24106815
Drug: Active infusion
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active infusion of ropivacaine 0.2% at 5 mL/hr via TAP catheter
Trial: 24106815
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo infusion via TAP catheter
Trial: 24106841
Drug: Living with
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Living with Hope Program (self-administered intervention including a film and a hope activity)
Trial: 24106922
Drug: Spinal anesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anesthesia with 1.8-2.0 ml of 0.75% ropivacaine plus 10 μg of fentanyl
Trial: 24108117
Drug: Severe sepsis
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe sepsis treatment (no specific intervention details provided)
Trial: 24109561
Drug: Internet-administered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-administered treatment based on guided physical exercise for Major Depressive Disorder (MDD)
Trial: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2, days 2-15
Trial: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) 75 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Trial: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 85 mg/m2, Capecitabine (CAP) 400 mg/m2
Trial: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) 150 mg/m2, Oxaliplatin (OX) 100 mg/m2, Capecitabine (CAP) 1600 mg/m2
Trial: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) 150 mg/m2
Trial: 24114122
Drug: Irinotecan (IRIN)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (IRIN) 100 mg/m2
Trial: 24114613
Drug: FOLFIRI-B chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI-B chemotherapy
Trial: 24114964
Drug: Platinum-based doublet
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based doublet therapy (carboplatin plus paclitaxel)
Trial: 24117272
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (radiochemotherapy)
Trial: 24118452
Drug: Anagrelide (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide (starting dose 1 mg/d in 52.6% of patients; 0.5 mg/d in 41.1%)
Trial: 24118452
Drug: Anagrelide after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anagrelide after discontinuing previous cytoreductive therapy (CRT)
Trial: 24119590
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart added to existing basal insulin (n=519)
Trial: 24119590
Drug: Switched from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switched from biphasic insulin (n=947)
Trial: 24119590
Drug: Insulin-naïve begun
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-naïve begun with basal plus insulin aspart (n=1594)
Trial: 24120120
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 fortified bread (125 μg daily) for 1 year
Trial: 24120338
Drug: Endoscopic hemostatic
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic hemostatic powder (21 g applied during endoscopy)
Trial: 24120380
Drug: Eltrombopag 75
RxNorm normalized name: eltrombopag 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag 75 mg, 150 mg, 225 mg, and 300 mg given orally once daily for 27 days
Trial: 24122237
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment during childhood
Trial: 24122387
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly (part I)
Trial: 24122387
Drug: Lenalidomide 10
RxNorm normalized name: lenalidomide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 10 mg daily and dexamethasone 8 mg once weekly plus rituximab 375 mg/m2 (part II)
Trial: 24122387
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (lenalidomide, low-dose dexamethasone, and rituximab)
Trial: 24123804
Drug: Platelet counts
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet counts < 60 × 10(9) /L on postoperative day 5 (POD5)
Trial: 24123804
Drug: Platelet counts
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet counts < 60 × 10(9) /L on POD5
Trial: 24126237
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) with risedronate
Trial: 24126237
Drug: Androgen deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Androgen deprivation therapy (ADT) without bisphosphonate therapy
Trial: 24127452
Drug: Pidilizumab (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pidilizumab (anti-PD-1 monoclonal antibody), administered as three doses beginning 1 to 3 months after AHSCT.
Trial: 24128118
Drug: Conventional drug-susceptibility
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug-susceptibility testing (DST)
Trial: 24128336
Drug: Low vitamin
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low vitamin A status (serum retinol <1·05 μmol/l)
Trial: 24128336
Drug: Middle vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Middle vitamin A tertile (1·056-1·298 μmol/l)
Trial: 24128669
Drug: BMS-626529 (an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-626529 (an attachment inhibitor administered as the prodrug BMS-663068)
Trial: 24130489
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy (ART) for 24 weeks
Trial: 24131779
Drug: Dinaciclib (0.33
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (0.33 mg/m2 to 14 mg/m2, 2-hour intravenous infusion once weekly for 3 weeks)
Trial: 24131779
Drug: Dinaciclib at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib at RP2D (12 mg/m2)
Trial: 24131779
Drug: Dinaciclib (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (various doses)
Trial: 24131779
Drug: Dinaciclib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinaciclib (all doses)
Trial: 24132613
Drug: Liraglutide 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.2 mg daily
Trial: 24134221
Drug: HIV-1-specific antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1-specific antibody responses to transmembrane glycoprotein (TM) and reverse transcriptase (RT)
Trial: 24134221
Drug: HIV-1-specific antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1-specific antibody responses to surface glycoprotein (SU), capsid (CA), matrix (MA), and integrase (IN)
Trial: 24134221
Drug: HIV-1-specific antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1-specific antibody responses to capsid (CA), matrix (MA), and integrase (IN)
Trial: 24134221
Drug: HIV-1-specific antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1-specific antibody responses to capsid (CA) and integrase (IN)
Trial: 24138944
Drug: Decitabine (DAC)
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine (DAC) 20mg/m² intravenously daily for 5 days followed by rapamycin at doses of 2 mg, 4 mg, and 6 mg/day from day 6 to day 25
Trial: 24139613
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy consisting of 2 cycles of cisplatin and etoposide combined with 45 Gy of thoracic radiotherapy
Trial: 24140121
Drug: ApoCell (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApoCell (higher doses)
Trial: 24144215
Drug: Dipyrone 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 15 mg/kg